The shareholders of Iason GmbH have completed a restructuring of the company and its refinancing efforts with local banks based on an IBR.
The Iason group produces radiopharmaceuticals and supplies special laboratory products to the target group "nuclear medicine" and "laboratory medicine" providing innovative products with the highest quality standards. The company has customers from all over Europe.
Oaklins' team in Austria assisted Iason with the preparation of the IBR (independent business review) and negotiations with local banks regarding refinancing possibilities.
© 2019 Oaklins. All rights reserved. Oaklins is the collective trade name of independent member firms affiliated with Oaklins International Inc. For details of the nature of affiliation, please refer to www.oaklins.com/legal.